No products in the cart.
Publication-Lipogene
Selected Publications using Genemed's LipoGene™ Transfection Reagent
| Publications | Link to the article | Products/Services |
| X. Ma et.al, ‘Hippo Signaling Promotes Jnk-Dependent Cell Migration’, Proc Natl Acad Sci U S A, 114 (2017), 1934-39. | http://www.ncbi.nlm.nih.gov/pubmed/28174264 | LipoGene™ Transfection Reagent |
| Y. Li et.al, ‘A Novel Epigenetic Aml1-Eto/Thap10/Mir-383 Mini-Circuitry Contributes to T(8;21) Leukaemogenesis’, EMBO Mol Med, 9 (2017), 933-49. | http://www.ncbi.nlm.nih.gov/pubmed/28539478 | LipoGene™ Transfection Reagent |
| Z. Yang et.al, ‘A Human Proteome Array Approach to Identifying Key Host Proteins Targeted by Toxoplasma Kinase Rop18’, Mol Cell Proteomics, 16 (2017), 469-84. | http://www.ncbi.nlm.nih.gov/pubmed/28087594 | LipoGene™ Transfection Reagent |
| X. Zhang et.al, ‘Long Non-Coding Rna Ufc1 Promotes Gastric Cancer Progression by Regulating Mir-498/Lin28b’, J Exp Clin Cancer Res, 37 (2018), 134. | http://www.ncbi.nlm.nih.gov/pubmed/29970131 | LipoGene™ Transfection Reagent |
| G. Deng et.al, ‘Bmp4 Promotes Hepatocellular Carcinoma Proliferation by Autophagy Activation through Jnk1-Mediated Bcl-2 Phosphorylation’, J Exp Clin Cancer Res, 37 (2018), 156. | http://www.ncbi.nlm.nih.gov/pubmed/30012194 | LipoGene™ Transfection Reagent |
| H. Zhang et.al, ‘Caf-Secreted Cxcl1 Conferred Radioresistance by Regulating DNA Damage Response in a Ros-Dependent Manner in Esophageal Squamous Cell Carcinoma’, Cell Death Dis, 8 (2017), e2790. | http://www.ncbi.nlm.nih.gov/pubmed/28518141 | LipoGene™ Transfection Reagent |
| Y. He et.al, ‘Adeno-Associated Virus 9-Mediated Cdk5 Inhibitory Peptide Reverses Pathologic Changes and Behavioral Deficits in the Alzheimer’s Disease Mouse Model’, FASEB J, 31 (2017), 3383-92. | http://www.ncbi.nlm.nih.gov/pubmed/28420695 | LipoGene™ Transfection Reagent |
| N. Wang et.al, ‘Direct Inhibition of Actn4 by Ellagic Acid Limits Breast Cancer Metastasis Via Regulation of Beta-Catenin Stabilization in Cancer Stem Cells’, J Exp Clin Cancer Res, 36 (2017), 172. | http://www.ncbi.nlm.nih.gov/pubmed/29197410 | LipoGene™ Transfection Reagent |
| D. S. Wu et.al, ‘Atf2 Predicts Poor Prognosis and Promotes Malignant Phenotypes in Renal Cell Carcinoma’, J Exp Clin Cancer Res, 35 (2016), 108. | http://www.ncbi.nlm.nih.gov/pubmed/27377902 | LipoGene™ Transfection Reagent |
| L. Liu et.al, ‘Synthetic Bax-Anti Bcl2 Combination Module Actuated by Super Artificial Htert Promoter Selectively Inhibits Malignant Phenotypes of Bladder Cancer’, J Exp Clin Cancer Res, 35 (2016), 3. | http://www.ncbi.nlm.nih.gov/pubmed/26743236 | LipoGene™ Transfection Reagent |
| Y. Zhang et.al, ‘Clinical Significance and Effect of Aeg-1 on the Proliferation, Invasion, and Migration of Nsclc: A Study Based on Immunohistochemistry, Tcga, Bioinformatics, in Vitro and in Vivo Verification’, Oncotarget, 8 (2017), 16531-52. | http://www.ncbi.nlm.nih.gov/pubmed/28152520 | LipoGene™ Transfection Reagent |
| L. Liu et.al, ‘Inhibiting Cell Migration and Cell Invasion by Silencing the Transcription Factor Ets-1 in Human Bladder Cancer’, Oncotarget, 7 (2016), 25125-34. | http://www.ncbi.nlm.nih.gov/pubmed/27036016 | LipoGene™ Transfection Reagent |
| W. Li et.al, ‘Mirna-99b-5p Suppresses Liver Metastasis of Colorectal Cancer by Down-Regulating Mtor’, Oncotarget, 6 (2015), 24448-62. | http://www.ncbi.nlm.nih.gov/pubmed/26259252 | LipoGene™ Transfection Reagent |
| S. Wen et.al, ‘P53 Increase Mitochondrial Copy Number Via up-Regulation of Mitochondrial Transcription Factor a in Colorectal Cancer’, Oncotarget, 7 (2016), 75981-95. | http://www.ncbi.nlm.nih.gov/pubmed/27732955 | LipoGene™ Transfection Reagent |
| C. Du et.al, ‘Polyethyleneimine-Capped Silver Nanoclusters for Microrna Oligonucleotide Delivery and Bacterial Inhibition’, Int J Nanomedicine, 12 (2017), 8599-613. | http://www.ncbi.nlm.nih.gov/pubmed/29238194 | LipoGene™ Transfection Reagent |
